Table 2 Immune-related adverse events of this study population.
n | Median duration | Grade 1, n (%) | Grade 2, n (%) | ≥ Grade 3, n (%) | Corticosteroid treatment*, n (%) | Hormone replacement†, n (%) | ||
|---|---|---|---|---|---|---|---|---|
Day | Range | |||||||
Total | 166 | 77 | 3–1029 | 66 (39.8) | 69 (41.6) | 31 (18.7) | 43 (25.9) | 31 (18.7) |
irAE subtype | ||||||||
Rash | 44 | 46 | 4–706 | 28 (63.6) | 12 (27.3) | 4 (9.1) | 11 (25.0) | 0 (0.0) |
Pruritus | 13 | 87 | 24–771 | 9 (69.2) | 4 (30.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Vitiligo | 4 | 111 | 23–204 | 4 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Colitis/diarrhea | 9 | 87 | 7–697 | 3 (33.3) | 4 (44.4) | 2 (22.2) | 3 (33.3) | 0 (0.0) |
Thyroiditis | 17 | 60 | 23–65 | 1 (5.9) | 16 (94.1) | 0 (0.0) | 0 (0.0) | 16 (94.1) |
Hypophysitis | 12 | 266 | 88–1029 | 0 (0.0) | 10 (83.3) | 2 (16.7) | 0 (0.0) | 12 (100.0) |
Type 1 diabetes | 3 | 192 | 124–407 | 0 (0.0) | 0 (0.0) | 3 (100.0) | 0 (0.0) | 3 (100.0) |
Pneumonitis | 26 | 70 | 8–361 | 11 (42.3) | 6 (23.1) | 9 (34.6) | 15 (57.7) | 0 (0.0) |
Liver dysfunction | 5 | 40 | 4–113 | 1 (20.0) | 0 (0.0) | 4 (80.0) | 2 (40.0) | 0 (0.0) |
Renal dysfunction | 3 | 35 | 17–64 | 1 (33.3) | 1 (33.3) | 1 (33.3) | 1 (33.3) | 0 (0.0) |
Neuropathy | 2 | 238 | 3–472 | 0 (0.0) | 2 (100.0) | 0 (0.0) | 1 (50.0) | 0 (0.0) |
RA | 3 | 259 | 20–331 | 2 (66.7) | 1 (33.3) | 0 (0.0) | 1 (33.3) | 0 (0.0) |
RS3PE syndrome | 2 | 47 | 8–85 | 0 (0.0) | 2 (100.0) | 0 (0.0) | 2 (100.0) | 0 (0.0) |
Uveitis | 2 | 62 | 46–78 | 1 (50.0) | 1 (50.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Myocarditis | 2 | 127 | 127 | 0 (0.0) | 1 (50.0) | 1 (50.0) | 0 (0.0) | 0 (0.0) |
Amylase/lipase increase | 2 | 91 | 60–122 | 0 (0.0) | 2 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Others | 17 | 85 | 9–281 | 5 (29.4) | 7 (41.2) | 5 (29.4) | 7 (41.2) | 0 (0.0) |
